Clinical Trials Logo
  1. Home
  2. Renal Transplantation
  3. NCT02108301
  4. Details
NCT02108301 Clinical Trial

Hepatitis C in Renal Transplant Recipients

Renal Transplantation Clinical Trial

Official title:
Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial.

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT02108301
Other study ID # EK477/2011
Secondary ID
Status Active, not recruiting
Phase Phase 4
First received April 1, 2014
Last updated April 10, 2014
Start date December 2011

Study information
Verified date April 2014
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority Austria: EthikkommissionAustria: Agency for Health and Food Safety
Study type Interventional

Clinical Trial Summary

The aim of the present trial is to evaluate whether the conversion of immunosuppression from tacrolimus to cyclosporine A induces changes in (i) hepatitis C-virus load, (ii) parameters of hepatic function and (iii) parameters of glucose tolerance in hepatitis C-positive renal transplant recipients.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 30
Est. completion date
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- written informed consent

- prior renal transplantation

- current tacrolimus-based immunosuppressive regimen

- hepatitis C-infection

- age 18-70 years

Exclusion Criteria:

- current hemodialysis or peritoneal dialysis

- pregnancy or breastfeeding

- known contraindication for cyclosporine A-treatment

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• tacrolimus-cyclosporine A
conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients

Locations
Country Name City State
Austria Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis Vienna

Sponsors (1)
Lead Sponsor Collaborator
Prof. Dr. Alice Schmidt

Country where clinical trial is conducted

Austria, 

Outcome
Type Measure Description Time frame Safety issue
Other serum creatinine levels 12 weeks Yes
Other serum glutamic-pyruvic transaminase concentrations 12 weeks Yes
Primary change in Hepatitis C-virus load at 12 weeks one day before and 4, 8 and 12 weeks after the conversion No
Secondary change in oral glucose insulin sensitivity (OGIS) index at 12 weeks one day before and 12 weeks after the conversion No
Secondary change in serum hepcidin levels at 12 weeks one day before and 12 weeks after the conversion No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06026592 - Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
Active, not recruiting NCT02444429 - 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation Phase 3
Completed NCT02238418 - Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria. Phase 4
Completed NCT01729494 - Belatacept Early Steroid Withdrawal Trial Phase 4
Terminated NCT01436305 - Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation Phase 2
Terminated NCT01276834 - Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation Phase 4
Completed NCT02843295 - Catalytic Antibodies to Predict Uninvasively Late Transplant Failure N/A
Completed NCT00842699 - Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab N/A
Completed NCT00525681 - Interaction Between Rimonabant and Cyclosporine and Tacrolimus Phase 4
Completed NCT00776750 - Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients Phase 4
Completed NCT00189735 - A Study to Evaluate FK778 in Kidney Transplant Patients Phase 2
Recruiting NCT04052867 - Intravenous Lignocaine Infusion in Laparoscopic Donor Nephrectomy N/A
Recruiting NCT03114826 - Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients N/A
Completed NCT02587052 - A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac
Completed NCT02020642 - Effect of Renal Transplantation on Obstructive Sleep Apnea in End Stage Renal Disease Patients (SASinTx) N/A
Completed NCT01435291 - AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation Phase 4
Recruiting NCT01001065 - Association of the Intrarenal Resistance Index (RI) of Transplanted Kidneys With Generalized Atherosclerosis N/A
Completed NCT00978965 - Identification of Patients With High Probability of Poorly Responding to Therapy With Mycophenolic Acid Prodrugs
Recruiting NCT00903188 - Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation Phase 4
Completed NCT00400400 - Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance Phase 4